eurofins scientific se - ERFSF

ERFSF

Close Chg Chg %
47.08 0.81 1.72%

Pre-Market

47.89

+0.81 (1.72%)

Volume: 978.00

Last Updated:

Nov 21, 2024, 2:57 PM EDT

Company Overview: eurofins scientific se - ERFSF

ERFSF Key Data

Open

$47.13

Day Range

47.13 - 51.07

52 Week Range

44.61 - 68.45

Market Cap

$9.01B

Shares Outstanding

191.37M

Public Float

127.80M

Beta

0.79

Rev. Per Employee

N/A

P/E Ratio

22.10

EPS

$0.54

Yield

114.87%

Dividend

$1.09

EX-DIVIDEND DATE

Jul 3, 2023

SHORT INTEREST

N/A

AVERAGE VOLUME

4.01K

 

ERFSF Performance

1 Week
 
3.30%
 
1 Month
 
-5.13%
 
3 Months
 
-21.10%
 
1 Year
 
-20.77%
 
5 Years
 
-7.65%
 

ERFSF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About eurofins scientific se - ERFSF

Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.

ERFSF At a Glance

Eurofins Scientific SE
23 Val Fleuri
Luxembourg, Luxembourg 1526
Phone 352-26-18-53-20 Revenue 7.04B
Industry Miscellaneous Commercial Services Net Income 335.47M
Sector Commercial Services Employees 61,798
Fiscal Year-end 12 / 2024
View SEC Filings

ERFSF Valuation

P/E Current 22.104
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 37.476
Price to Sales Ratio 1.831
Price to Book Ratio 2.778
Price to Cash Flow Ratio 12.59
Enterprise Value to EBITDA 13.024
Enterprise Value to Sales 2.421
Total Debt to Enterprise Value 0.319

ERFSF Efficiency

Revenue/Employee 113,968.667
Income Per Employee 5,428.496
Receivables Turnover 3.943
Total Asset Turnover 0.618

ERFSF Liquidity

Current Ratio 1.445
Quick Ratio 1.38
Cash Ratio 0.576

ERFSF Profitability

Gross Margin 9.523
Operating Margin 8.393
Pretax Margin 6.492
Net Margin 4.763
Return on Assets 2.944
Return on Equity 7.466
Return on Total Capital 3.373
Return on Invested Capital 3.789

ERFSF Capital Structure

Total Debt to Total Equity 120.826
Total Debt to Total Capital 54.716
Total Debt to Total Assets 45.246
Long-Term Debt to Equity 106.085
Long-Term Debt to Total Capital 48.04
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Eurofins Scientific Se - ERFSF

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
6.20B 7.94B 7.05B 7.04B
Sales Growth
+21.41% +28.07% -11.16% -0.16%
Cost of Goods Sold (COGS) incl D&A
5.20B 6.34B 6.19B 6.37B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
563.49M 620.78M 638.15M 718.19M
Depreciation
407.20M 465.46M 468.52M 543.04M
Amortization of Intangibles
156.29M 155.31M 169.63M 175.14M
COGS Growth
+10.89% +21.97% -2.41% +2.98%
Gross Income
1.00B 1.60B 866.32M 670.72M
Gross Income Growth
+139.29% +59.74% -45.83% -22.58%
Gross Profit Margin
+16.15% +20.14% +12.28% +9.52%
2020 2021 2022 2023 5-year trend
SG&A Expense
43.55M 71.27M 41.41M 79.57M
Research & Development
- - - -
-
Other SG&A
43.55M 71.27M 41.41M 79.57M
SGA Growth
-25.89% +63.67% -41.90% +92.16%
Other Operating Expense
- - - -
-
Unusual Expense
51.75M 40.90M 11.14M 16.65M
EBIT after Unusual Expense
905.82M 1.49B 813.77M 574.50M
Non Operating Income/Expense
(6.73M) (36.52M) 97.85M 11.03M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
109.44M 204.01M 92.80M 128.33M
Interest Expense Growth
+5.36% +86.42% -54.51% +38.28%
Gross Interest Expense
109.44M 204.01M 92.80M 128.33M
Interest Capitalized
- - - -
-
Pretax Income
789.66M 1.25B 818.81M 457.20M
Pretax Income Growth
+160.44% +57.85% -34.31% -44.16%
Pretax Margin
+12.74% +15.70% +11.61% +6.49%
Income Tax
175.44M 323.39M 183.08M 124.87M
Income Tax - Current - Domestic
193.00M 354.48M 211.46M 169.63M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(17.56M) (31.09M) (28.38M) (44.76M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
616.16M 925.49M 636.68M 332.77M
Minority Interest Expense
1.25M 472.79K (4.62M) (2.70M)
Net Income
614.90M 925.02M 641.30M 335.47M
Net Income Growth
+181.45% +50.43% -30.67% -47.69%
Net Margin Growth
+9.92% +11.65% +9.09% +4.76%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
614.90M 925.02M 641.30M 335.47M
Preferred Dividends
- - - -
-
Net Income Available to Common
614.90M 925.02M 641.30M 335.36M
EPS (Basic)
3.3024 4.8304 3.3315 1.7385
EPS (Basic) Growth
+169.06% +46.27% -31.03% -47.82%
Basic Shares Outstanding
186.20M 191.50M 192.50M 192.90M
EPS (Diluted)
3.1389 4.6113 3.2226 1.6946
EPS (Diluted) Growth
+167.23% +46.91% -30.12% -47.42%
Diluted Shares Outstanding
195.90M 200.60M 199.00M 197.90M
EBITDA
1.52B 2.15B 1.46B 1.31B
EBITDA Growth
+66.30% +41.26% -31.91% -10.51%
EBITDA Margin
+24.53% +27.06% +20.74% +18.59%

Eurofins Scientific Se in the News